ABT: Solid revenue growth

Our AI analyzes fundamentals, momentum, and sentiment to score each stock 0-100.

Abbott Laboratories (ABT): A Steady Healthcare Performer in 2025

Executive Summary

Abbott Laboratories is demonstrating robust financial health in a challenging healthcare market. With $43.11B in trailing twelve-month revenue and a strong 32.4% profit margin, the company shows resilience and consistent growth. The +6.9% revenue expansion signals a positive trajectory in the medical technology and diagnostics sector.

Profitability & Growth

Abbott's financial performance tells a story of steady expansion. Revenue grew by a solid 6.9% year-over-year, indicating the company is successfully navigating market complexities. The 32.4% profit margin is particularly impressive, showcasing operational efficiency that outpaces many competitors in the healthcare space.

Key profitability highlights:

• Net Income (TTM): $13.98B
• Earnings Per Share (TTM): $3.95
• Operating Margin: 19.39%

So what? These metrics reveal Abbott isn't just growing, but growing smartly—maximizing every dollar of revenue into sustainable profit.

Financial Health

The balance sheet paints a picture of financial stability:

• Total Assets: $74.36B
• Total Liabilities: $34.33B
• Stockholder Equity: $39.80B

The 32.2% debt-to-equity ratio demonstrates conservative financial management. With $7.8B in cash, Abbott maintains a strong liquidity position to weather economic uncertainties.

Cash Flow & Dividends

Cash flow metrics underscore the company's financial strength:

• Operating Cash Flow (TTM): $9.04B
• Free Cash Flow (TTM): $6.78B
• Dividend Yield: 1.99%

The robust free cash flow suggests Abbott can comfortably fund operations, invest in R&D, and return value to shareholders through dividends.

Valuation & Forecast

Valuation metrics reveal an attractively priced healthcare performer:

• P/E Ratio (TTM): 15.94
• Price/Sales: 5.03
• Revenue Forecast (Next Year): $48.22B

Analyst estimates point to continued growth, with EPS expected to rise from $5.15 to $5.68 in the next year.

Verdict

Bull Case: Strong margins, consistent growth, and robust cash flow position Abbott as a resilient healthcare investment.

Bear Case: Potential market saturation and competitive pressures could challenge future expansion.

Balanced Perspective: Abbott demonstrates financial discipline and steady growth, making it an attractive option for investors seeking stability in the healthcare sector.

Confidence Level: 85% based on current financial indicators and consistent performance.

Key Strengths

• Solid revenue growth
• High profit margins
• Low debt levels

Related Tickers